Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10013399 | 0.84 | POLB (0.46) | KMT2AKDM4EMEN1TSHR | |
| SCHEMBL1069207 | 0.82 | TP53 (0.55) | LMNAKMT2AMEN1 | |
| SCHEMBL7397891 | 0.82 | TP53 (0.55) | LMNAKMT2AMEN1 | |
| SCHEMBL10013398 | 0.80 | ALDH1A1 (0.53) | ALDH1A1NPC1RAB9AANPEPKMT2A | |
| SCHEMBL506094 | 0.79 | TLR2 (0.52) | ALDH1A1NPC1RAB9AHTT | |
| SCHEMBL506095 | 0.79 | TLR2 (0.52) | ALDH1A1NPC1RAB9AHTT | |
| SCHEMBL10013375 | 0.78 | PSMB5 (0.46) | KMT2A | |
| SCHEMBL10013396 | 0.78 | MEN1 (0.49) | ALDH1A1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL6325943 | 0.76 | ALDH1A1 (0.57) | ALDH1A1NPC1RAB9AANPEPLMNA | |
| SCHEMBL8935308 | 0.75 | PDCD1 (0.44) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853452-B2 | Compounds, their syntheses, compositions, and methods to treat cancer | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2014-10-07 | — | — | US | disclosed |
| US-20120027844-A1 | COMPOUNDS, THEIR SYNTHESES, COMPOSITIONS, AND METHODS TO TREAT CANCER | XAVIER UNIVERSITY OF LOUISIANA (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027844-A1 | COMPOUNDS, THEIR SYNTHESES, COMPOSITIONS, AND METHODS TO TREAT CANCER | XAVIER UNIVERSITY OF LOUISIANA (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120027844-A1 | COMPOUNDS, THEIR SYNTHESES, COMPOSITIONS, AND METHODS TO TREAT CANCER | SGMS1, PHOSPHO1, MCL1 | ALDH1A1 3249/4885NPC1 33/4885RAB9A 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.